Serum protein profiles of patients with lung cancer of different histological types
Open Access
- 15 December 2015
- journal article
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 12 (1) , 70-76
Abstract
Aims: To compare serum protein expression profiles between lung cancer patients and healthy individuals, and to examine whether there are differences in serum protein expression profiles among patients with lung cancers of different histological types and whether the characteristic expression of serum proteins may assist in differential diagnosis of various subtypes of lung cancers. Methods: Blood samples were collected from 123 lung cancer patients before commencement of treatment who attended Shanxi Cancer Hospital, China, between 2008 and 2013. Blood samples from 60 healthy individuals were also collected in the same period. Serum protein expression profiles were analyzed using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. The differences in the serum protein spectrums of lung cancer patients with different histological subtypes were analyzed by one-way Analysis of Variance and receiver operating characteristic curves. Results: A cluster of 48 protein mass-to-change ratio (M/Z) peaks was differentially expressed between sera of lung cancer patients and healthy individuals. The M/Z 1205, 4673, 1429 and 4279 peaks were differentially expressed among patients with lung squamous cell carcinomas, adenocarcinomas and small-cell lung carcinomas. Conclusion: These results reinforce the notion that profiling of serum proteins may be of diagnostic value in lung cancer, and suggest that the differences in serum protein profiles may be useful in differential diagnosis of lung cancers of varying histological subtypesKeywords
Funding Information
- Scientific and Technological Project of Shanxi Province (2013-133)
This publication has 35 references indexed in Scilit:
- Lung Cancer in ChinaChest, 2013
- Early Detection of Lung Cancer Risk Using Data MiningAsian Pacific Journal of Cancer Prevention, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyThe Lancet Oncology, 2012
- Molecular diagnostics and personalized medicine in oncology: Challenges and opportunitiesJournal of Cellular Biochemistry, 2012
- Pathology of Lung CancerClinics in Chest Medicine, 2011
- Today's lifestyles, tomorrow's cancers: trends in lifestyle risk factors for cancer in low- and middle-income countriesAnnals of Oncology, 2011
- Global Patterns of Cancer Incidence and Mortality Rates and TrendsCancer Epidemiology, Biomarkers & Prevention, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008